# US 2019/0054155 A1 · Enzymes And Methods For Cleaving N-Glycans From Glycoproteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054155 A1
- Document ID: US20190054155A1
- Status: Published application
- Kind: A1
- Application number: 16/058,898
- Filed: 2018-08-08
- Published: 2019-02-21
- Earliest claimed: 2012-02-14
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Daniel GARRIDO; J. Bruce GERMAN; Carlito B. LEBRILLA; David A. MILLS
- Web page: https://patentgrep.com/patent/US20190054155A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A23C 9/1216: {Other enzymes}
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/195: Proteins from microorganisms
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 9/2497: {hydrolysing N- glycosyl compounds (3.2.2)}
- C12P 19/04: Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C12P 21/005: {Glycopeptides, glycoproteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Y 302/01096: Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y02P 20/52: using catalysts, e.g. selective catalysts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A composition comprising:
a GH18 endoglycosidase-comprising SEQ ID NO:1; and
an allergenic glycoprotein.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the GH18 endoglycosidase is an endo-β-N-acetylglucosaminidase.

### Claim 21 (depends on 19)

The composition of claim 19, wherein the GH18 endoglycosidase comprises a polypeptide at least 90% identical to SEQ ID NO:4 or SEQ ID NO:5.

### Claim 22 (depends on 19)

The composition of claim 19, wherein the GH18 endoglycosidase comprises SEQ ID NO:4 or SEQ ID NO:5.

### Claim 23 (depends on 19)

The composition of claim 19, wherein the allergenic glycoprotein is a milk, plant, egg, or nut glycoprotein.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the plant glycoprotein is a soy glycoprotein.

### Claim 25

A composition comprising a deglycosylated protein made by the method of contacting a glycoprotein with a GH18 endoglycosidase comprising SEQ ID NO:1, wherein high mannose glycans, complex glycans, hybrid N-glycans, or a combination thereof are removed from the glycoprotein, thereby generating the deglycosylated protein.

### Claim 26

The composition of 25, wherein said deglycosylated protein is separated or purified from the GH18 endoglycosidase.

### Claim 27 (depends on 25)

The composition of claim 25, wherein the deglycosylated protein has lower allergenicity than the glycoprotein.

### Claim 28 (depends on 25)

The composition of claim 25, wherein the food composition is a powder.

### Claim 29

A composition comprising released N-glycans, wherein the released N-glycans are generated by contacting a glycoprotein with a GH18 endoglycosidase comprising SEQ ID NO:1.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the released N-glycans are separated from the protein and the GH18 endoglycosidase.

### Claim 31 (depends on 29)

The composition of claim 29, wherein the GH18 endoglycosidase is an endo-β-N-acetylglucosaminidase.

### Claim 32 (depends on 29)

The composition of claim 29, wherein the GH18 endoglycosidase comprises a polypeptide at least 90% identical to SEQ ID NO:4 or SEQ ID NO:5.

### Claim 33 (depends on 29)

The composition of claim 29, wherein the GH18 endoglycosidase comprises SEQ ID NO:4 or SEQ ID NO:5.

### Claim 34 (depends on 29)

The composition of claim 29, wherein the glycoprotein is a milk, plant, egg, nut glycoprotein.

### Claim 35 (depends on 33)

The composition of claim 33, wherein the plant glycoprotein is a soy glycoprotein.

### Claim 36 (depends on 29)

The composition of claim 29, wherein the released N-glycans comprise one or more of:
a. an oligosaccharide consisting of 3 Hex (glucose, galactose, or mannose) moieties and 5 HexNAc (GlcNac or GalNAc) moieties;
b. an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties;
c. an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties, and 1 NeuAc (N-acetylneuraminic acid) moiety;
d. an oligosaccharide consisting of 5 Hex moieties, 3 HexNAc moieties, and 1 NeuAc moiety;
e. an oligosaccharide consisting of 4 Hex moieties, 3 HexNAc moieties, and 1 NeuAc moiety;
f. an oligosaccharide consisting of 3 Hex moieties, 5 HexNAc moieties, and 1 NeuAc moiety;
g. an oligosaccharide consisting of 5 Hex moieties, 1 Fuc (fucose) moiety, 3 HexNAc moieties, and 1 NeuGc (N-glycoylneuraminic acid) moiety; and
h. an oligosaccharide consisting of 5 Hex moieties, 3 HexNAc moieties, and 2 NeuAc moieties.

### Claim 37 (depends on 29)

The composition of claim 29, wherein the food composition is a powder.

### Claim 38 (depends on 29)

The composition of claim 29, further comprising a fructoligosaccharide, lactose, xylooligosaccharide, soyoligosaccharide, lactulose or lactitol.

### Claim 39 (depends on 29)

The composition of claim 29, further comprising a Bifidobacterium selected from the group B. longum bv. infantis, B. longum bv. longum, B. adolescentis, or B. breve
